Capreomycin sulfate: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) |
||
| Line 25: | Line 25: | ||
'''| [[Capreomycin sulfate labels and packages|Labels and Packages]]''' | '''| [[Capreomycin sulfate labels and packages|Labels and Packages]]''' | ||
== | ==Mechanism of Action== | ||
Capreomycin is a cyclic polypeptide antimycobacterial agent. The mechanism of action of capreomycin is postulated to interfere with several ribosomal functions including formation of the 30S subunit initiation complex and blockade of tRNA translocation from the A to the P site. Significant cross-resistance with [[viomycin]], [[kanamycin]], and [[neomycin]] occurs. | |||
==References== | ==References== | ||
Revision as of 00:12, 26 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Capreomycin is a peptide antibiotic, commonly grouped with the aminoglycosides, which is given in combination with other antibiotics for MDR-tuberculosis. Adverse effects include nephrotoxicity and 8th cranial auditory vestibular nerve nerve toxicity.
Category
Antimycobacterial
US Brand Names
CAPASTAT SULFATE®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
Capreomycin is a cyclic polypeptide antimycobacterial agent. The mechanism of action of capreomycin is postulated to interfere with several ribosomal functions including formation of the 30S subunit initiation complex and blockade of tRNA translocation from the A to the P site. Significant cross-resistance with viomycin, kanamycin, and neomycin occurs.